NewswireToday - /newswire/ -
Heerlen, NL, United States, 2012/12/06 - Royal DSM, the global Life Sciences and Materials Sciences company, announced today that it has successfully completed the acquisition of Cargillís cultures and enzymes business - DSM.com. Euronext: DSM KON
The acquisition, announced on 26 October 2012, will enable DSM to become a global tier one dairy ingredients supplier.
A variety of cheeses on a cheese board
The cultures and enzymes business of Cargill is a global leading manufacturer of cultures and enzymes for the dairy and meat industries with manufacturing operations in Wisconsin (USA) and France. It has a strong pipeline of new products built on three pillars of technology: culture texture toolbox, fast acidification for cheese yield improvements and culture flavor systems. The business generates net sales of about Ä45 million per year with approximately 200 employees.
The market for cultures and enzymes is valued at over Ä1 billion, growing steadily at more than 5% per annum. Applications are primarily found in dairy products which continue to have a healthy and tasty appeal to consumers worldwide. The growing diversity of dairy products requires versatile culture offerings enhancing taste, texture and mouth feel characteristics as well as health benefits (lower fat, less sugar, etc.) and convenience.
By combining Cargillís cultures and enzymes business with the dairy business of DSM Food Specialties, a strong global player will be created, enabling DSM to accelerate sales and capture meaningful synergies in global manufacturing and customer reach as well as innovation capabilities in biotechnology and SG&A.
The combination of the two businesses will allow DSM to achieve its ambition to become a tier one supplier of cultures and enzymes to the global dairy market and will greatly accelerate DSMís growth plans for its business, which continues to benefit from strong consumer demand for more versatile dairy products. The acquisition further strengthens DSMís global position in dairy ingredients with enzymes, PUFAs, vitamins, cultures, probiotics, bio actives, preservation systems and tests.
DSM Investor Relations
T: +31 (0)45 578 2864 - E: investor.relations[.]dsm.com.